Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

A post-hoc analysis of the phase 3 AMAGINE-2 and AMAGINE-3 trials including 3,712 people with moderate-to-severe psoriasis showed that 90% of patients treated with brodalumab who achieved Psoriasis Area and Severity Index (PASI) score of 100 also experienced a sustained PASI-100 score [1].

In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI-100 also experienced sustained PASI-100. The authors measured sustained PASI-100 as the time to inadequate response, based on a static physician’s global assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week period or after week 16. Since the subpopulations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the authors did not apply statistical comparisons.

“Newer treatments for moderate-to-severe psoriasis have made it possible for patients to completely clear their skin, but the disease fluctuates over time; so we wanted to explore how fast and for how long patients can count on having complete skin clearance,” said Prof. Lluís Puig (Hospital de la Santa Creu i Sant Pau, Spain). “These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab. That difference can have a big impact on patients’ quality of life.”

1. 
   
   1. Warren, R. et al. P069, SPIN 2019, 25-27 April, Paris, France.

Posted on 21 June, 20196 September, 2023